Our Expertise

Delivering fully validated biosimilar assets with supporting
data to jump start your development efforts.


Discover Our


Our differentiated approach enables rapid biosimilar target selection, accelerates Chemistry, Manufacturing, and Controls development timelines, and reduces preclinical cost and risk. Learn more about our programs by exploring our pipelines.

  • Analytical Data Pipeline

    Our analytical packages deliver reference product QTPP, stability data, and analytical methods at a lower cost than independent generation.

    Learn More

  • Asset Development Pipeline

    Early initiation of biosimilar development, coupled with our robust data packages, enables us to develop high quality products ready to out-license.

    Learn More

Maximize Value Through

Flexible Partnership

Reduce risk during early biosimilar development, cut costs for analytical activities, and accelerate early programs.

Are you looking for a program beyond our current pipeline but you are concerned with risks from program cancellation and market timelines? Discuss a co-development agreement with Similis to initiate the development of multiple biosimilar programs in parallel with an exclusive right to every program.

Discover More


Let's Discuss Biosimilars